![Ba Xian Yi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ba Xian Yi
Directeur/Membre du Conseil chez
Shanghai Pudong Science & Technology Investment Co. Ltd.
Profil
Ba Xian Yi is currently the Managing Partner at Shanghai Pudong Science & Technology Investment Co. Ltd. He previously served as an Independent Director at Shanghai Medicilon, Inc. from 2015 to 2021.
Prior to that, he was the Director at Sichuan Industrial Institute of Antibiotics from 2007 to 2010.
In 2022, he will be an Independent Non-Executive Director at Boill Healthcare Holdings Ltd. He also held the position of Vice President at China State Institute of Pharmaceutical Industry from 2010 to 2015.
Dr. Yi's education includes a graduate degree from Shaanxi Master of Business Administration Institute and undergraduate, graduate, and doctorate degrees from China Pharmaceutical University.
Postes actifs de Ba Xian Yi
| Sociétés | Poste | Début |
|---|---|---|
Shanghai Pudong Science & Technology Investment Co. Ltd.
 Shanghai Pudong Science & Technology Investment Co. Ltd. Investment ManagersFinance Shanghai Pudong Science and Technology Investment Co., Ltd. (PDSTI) is an active manager which seeks to invest in leading companies specialized in high-tech industries, providing capital to businesses through a range of transactions including buyouts, turnarounds, public-to-private transactions, mergers and growth expansions. The firm partners with management to increase profitability and free cash flow generation, enhance entry barriers and improve market position through selective asset investments, pursue strategies to increase asset attractiveness for exit, develop capital structures and establish relationships with industry specialists. They invest in companies with a proven business model, an established customer base, the ability to generate cash flows, the potential to become a leader in the sector, a need to accelerate growth via organic development or consolidation of fragmented sectors, outstanding management willing to commit significant resources to make the company reach the next level of development. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ba Xian Yi
| Sociétés | Poste | Fin |
|---|---|---|
| BOILL HEALTHCARE HOLDINGS LIMITED | Directeur/Membre du Conseil | 22/07/2024 |
| SHANGHAI MEDICILON INC. | Directeur/Membre du Conseil | 01/12/2021 |
China State Institute of Pharmaceutical Industry
 China State Institute of Pharmaceutical Industry Pharmaceuticals: MajorHealth Technology Regulates pharmaceutical companies | Corporate Officer/Principal | 01/01/2015 |
Sichuan Industrial Institute of Antibiotics
 Sichuan Industrial Institute of Antibiotics Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | 01/12/2010 |
Sinopharm Holding Co., Ltd.
 Sinopharm Holding Co., Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Formation de Ba Xian Yi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Shanghai Pudong Science & Technology Investment Co. Ltd.
Shanghai Pudong Science & Technology Investment Co. Ltd. Investment ManagersFinance Shanghai Pudong Science and Technology Investment Co., Ltd. (PDSTI) is an active manager which seeks to invest in leading companies specialized in high-tech industries, providing capital to businesses through a range of transactions including buyouts, turnarounds, public-to-private transactions, mergers and growth expansions. The firm partners with management to increase profitability and free cash flow generation, enhance entry barriers and improve market position through selective asset investments, pursue strategies to increase asset attractiveness for exit, develop capital structures and establish relationships with industry specialists. They invest in companies with a proven business model, an established customer base, the ability to generate cash flows, the potential to become a leader in the sector, a need to accelerate growth via organic development or consolidation of fragmented sectors, outstanding management willing to commit significant resources to make the company reach the next level of development. | Finance |
Shaanxi Master of Business Administration Institute
 Shaanxi Master of Business Administration Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
China Pharmaceutical University
 China Pharmaceutical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shanghai Medicilon, Inc.
 Shanghai Medicilon, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and develop biotechnology drug discovery contract research organization | Commercial Services |
China State Institute of Pharmaceutical Industry
China State Institute of Pharmaceutical Industry Pharmaceuticals: MajorHealth Technology Regulates pharmaceutical companies | Health Technology |
Sichuan Industrial Institute of Antibiotics
Sichuan Industrial Institute of Antibiotics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boill Healthcare Holdings Ltd.
 Boill Healthcare Holdings Ltd. Real Estate DevelopmentFinance Operates as an investment holding company with interests in engaging in healthcare holiday resort development, foundation piling, property development and securities investment business | Finance |
Sinopharm Holding Co., Ltd.
Sinopharm Holding Co., Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
